Oncolytics Biotech is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March. At this time, Oncolytics Biotech's Common Stock is fairly stable compared to the past year. Key indicators impacting Oncolytics Biotech's financial strength include:
The essential information of the day-to-day investment outlook for Oncolytics Biotech includes many different criteria found on its balance sheet. An individual investor should monitor Oncolytics Biotech's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Oncolytics Biotech.
Please note, the imprecision that can be found in Oncolytics Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Oncolytics Biotech. Check Oncolytics Biotech's Beneish M Score to see the likelihood of Oncolytics Biotech's management manipulating its earnings.
Oncolytics Biotech Stock Summary
Oncolytics Biotech competes with Scpharmaceuticals, Milestone Pharmaceuticals, Seres Therapeutics, DiaMedica Therapeutics, and Inhibikase Therapeutics. Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada. Oncolytics Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Cash flow analysis captures how much money flows into and out of Oncolytics Biotech. It measures of how well Oncolytics is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Oncolytics Biotech brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Oncolytics had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Oncolytics Biotech has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining Oncolytics Biotech's current stock value. Our valuation model uses many indicators to compare Oncolytics Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Oncolytics Biotech competition to find correlations between indicators driving Oncolytics Biotech's intrinsic value. More Info.
Oncolytics Biotech is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Oncolytics Biotech's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Oncolytics Biotech's earnings, one of the primary drivers of an investment's value.
Oncolytics Biotech Systematic Risk
Oncolytics Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Oncolytics Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Oncolytics Biotech correlated with the market. If Beta is less than 0 Oncolytics Biotech generally moves in the opposite direction as compared to the market. If Oncolytics Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Oncolytics Biotech is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Oncolytics Biotech is generally in the same direction as the market. If Beta > 1 Oncolytics Biotech moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Oncolytics Biotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Oncolytics Biotech's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Oncolytics Biotech growth as a starting point in their analysis.
Oncolytics Biotech February 26, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Oncolytics Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Oncolytics Biotech. We use our internally-developed statistical techniques to arrive at the intrinsic value of Oncolytics Biotech based on widely used predictive technical indicators. In general, we focus on analyzing Oncolytics Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Oncolytics Biotech's daily price indicators and compare them against related drivers.
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.